Safety and Effectiveness of Darunavir in Korean Patients with Human Immunodeficiency Virus 1 Infection: A Post-Marketing Observational Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
We aimed to evaluate the safety and effectiveness of darunavir (DRV) in the treatment of human immunodeficiency virus-1 (HIV-1) infection in Korea. From October 29, 2010, 225 eligible patients with HIV-1 infection receiving DRV were enrolled. DRV was administered with other antiretroviral agents, and followed for 24 weeks. The primary objective was safety evaluation, and effectiveness was assessed by viral load and CD4 T cell counts after 12 weeks and 24 weeks. Adverse drug reactions occurred in 18 patients (9.2%); diarrhea was the most common. Viral load was controlled (<400 copies/mL) in 90.9% of patients. CD4 T cell counts were increased 45.0/mm3 significantly at Week 12 (P = 0.0002), and 70.5/mm3 at Week 24 (P <0.0001). DRV safety and effectiveness was consistent with previous studies.
Abstract
We aimed to evaluate the safety and effectiveness of darunavir (DRV) in the treatment of human immunodeficiency virus-1 (HIV-1) infection in Korea. From October 29, 2010, 225 eligible patients with HIV-1 infection receiving DRV were enrolled. DRV was administered with other antiretroviral agents, and followed for 24 weeks. The primary objective was safety evaluation, and effectiveness was assessed by viral load and CD4 T cell counts after 12 weeks and 24 weeks. Adverse drug reactions occurred in 18 patients (9.2%); diarrhea was the most common. Viral load was controlled (<400 copies/mL) in 90.9% of patients. CD4 T cell counts were increased 45.0/mm3 significantly at Week 12 (P = 0.0002), and 70.5/mm3 at Week 24 (P <0.0001). DRV safety and effectiveness was consistent with previous studies.
참고문헌 (15)
- Bánhegyi D, "Week 96 efficacy, virology and safety of darunavir", r versus lopinavir, Curr HIV Res, pp.2012, 10[DOI]
- Madruga JV, "Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial", Lancet, 370, pp.49~58 (2007)
- Mills AM, "Once-daily darunavir", ritonavir vs. lopinavir, AIDS, pp.2009, 23[DOI]
- Orkin C, "Final 192-week efficacy and safety of once-daily darunavir", ritonavir compared with lopinavir, HIV Med, pp.2013, 14[DOI]
- "Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"[URL]
- illig JH, "Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks", AIDS Res Hum Retroviruses, 26, pp.1279~1285 (2010)
- Benea OE, "Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study", Germs, 4, pp.59~69 (2014)
- Podzamczer D, ". Abacavir", lamivudine plus darunavir, J Antimicrob Chemother, pp.2014, 69[DOI]
- Antinori A, "Effectiveness, durability, and safety of darunavir", ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study, 2016, pp.10, 1589~1603
- 안해원, "Safety and Effectiveness Analysis of Kivexa® (lamivudine", abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients, 2019, pp.51(2), 150~160[DOI]
- Tsiodras S, "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study", Arch Intern Med, 160, pp.2050~2056 (2000)
- Baker JV, "Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial", J Am Heart Assoc, 6, pp.e004987~ (2017)
- Ryom L, "Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study", Lancet HIV, 5, pp.e291~e300 (2018)
- Opsomer M, "Correction to: Evaluation of cardiovascular disease risk in HIV-1-infected patients treated with darunavir", Drugs R D, 18, pp.249~250 (2018)
- 안혜원, "Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients", Infection and Chemotherapy, 49(3), pp.205~212 (2017), 대한감염학회